Small molecule inhibitors for cancer metabolism: promising prospects to be explored

Abdel-Wahab AF, Mahmoud W, Al-Harizy RM (2019) Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol Res 150:104511. https://doi.org/10.1016/j.phrs.2019.104511CrossRefPubMed

Adams DJ, Ito D, Rees MG, Seashore-Ludlow B, Puyang X, Ramos AH et al (2014) NAMPT is the cellular target of STF-31-like small-molecule probes. ACS Chem Biol 9(10):2247–2254. https://doi.org/10.1021/cb500347pCrossRefPubMedPubMedCentral

Ahluwalia MS, Patton C, Stevens G, Tekautz T, Angelov L, Vogelbaum MA et al (2011) Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas. J Neurooncol 102(2):317–321. https://doi.org/10.1007/s11060-010-0325-3CrossRefPubMed

Ancey PB, Contat C, Meylan E (2018) Glucose transporters in cancer - from tumor cells to the tumor microenvironment. FEBS J 285(16):2926–2943. https://doi.org/10.1111/febs.14577CrossRefPubMed

Ashrafian H, Horowitz JD, Frenneaux MP (2007) Perhexiline. Cardiovasc Drug Rev 25:76–97. https://doi.org/10.1111/j.1527-3466.2007.00006.xCrossRefPubMed

Backus KM, Correia BE, Lum KM, Forli S, Horning BD, González-Páez GE et al (2016) Proteome-wide covalent ligand discovery in native biological systems. Nature 534(7608):570–574. https://doi.org/10.1038/nature18002CrossRefPubMedPubMedCentral

Bar-Peled L, Kemper EK, Suciu RM, Vinogradova EV, Backus KM, Horning BD et al (2017) Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer. Cell 171(3):696-709.e23. https://doi.org/10.1016/j.cell.2017.08.051CrossRefPubMedPubMedCentral

Benjamin D, Robay D, Hindupur SK, Pohlmann J, Colombi M, El-Shemerly MY et al (2018) Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells. Cell Rep 25(11):3047-3058.e4. https://doi.org/10.1016/j.celrep.2018.11.043CrossRefPubMedPubMedCentral

Bergman A, Carvajal-Gonzalez S, Tarabar S, Saxena AR, Esler WP, Amin NB (2020) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver-Targeting Acetyl-CoA Carboxylase Inhibitor (PF-05221304): A Three-Part Randomized Phase 1 Study. Clin Pharmacol Drug Dev 9(4):514–526. https://doi.org/10.1002/cpdd.782CrossRefPubMedPubMedCentral

Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z (2021) Lipid metabolism and cancer. J Exp Med 218(1):e20201606. https://doi.org/10.1084/jem.20201606CrossRefPubMed

Bose S, Ramesh V, Locasale JW (2019) Acetate Metabolism in Physiology, Cancer, and Beyond. Trends Cell Biol 29(9):695–703. https://doi.org/10.1016/j.tcb.2019.05.005CrossRefPubMedPubMedCentral

Bose S, Zhang C, Le A (2021) Glucose Metabolism in Cancer: The Warburg Effect and Beyond. Adv Exp Med Biol 1311:3–15. https://doi.org/10.1007/978-3-030-65768-0_1CrossRefPubMedPubMedCentral

Brenner AJ, Von Hoff DD, Infante JR, Patel MR, Jones SF, Burris HA et al (2015) First-in-Human Investigation of the Oral First-in-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640. JCO 33:615. https://doi.org/10.1200/jco.2015.33.15_suppl.tps2615CrossRef

Broadfield LA, Pane AA, Talebi A, Swinnen JV, Fendt SM (2021) Lipid metabolism in cancer: New perspectives and emerging mechanisms. Dev Cell 56(10):1363–1393. https://doi.org/10.1016/j.devcel.2021.04.013CrossRefPubMed

Butler LM, Mah CY, Machiels J, Vincent AD, Irani S, Mutuku SM et al (2021) Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. Cancer Res 81(19):4981–4993. https://doi.org/10.1158/0008-5472.CAN-20-3863CrossRefPubMed

Buyse C, Joudiou N, Warscotte A, Richiardone E, Mignion L, Corbet C et al (2022) Evaluation of Syrosingopine, an MCT Inhibitor, as Potential Modulator of Tumor Metabolism and Extracellular Acidification. Metabolites 12(6):557. https://doi.org/10.3390/metabo12060557CrossRefPubMedPubMedCentral

Cai S, Gao Z (2021) Atorvastatin inhibits proliferation and promotes apoptosis of colon cancer cells via COX-2/PGE2/β-Catenin Pathway. J BUON 26(4):1219–1225PubMed

Camici M, Garcia-Gil M, Pesi R, Allegrini S, Tozzi MG (2019) Purine-Metabolising Enzymes and Apoptosis in Cancer. Cancers (basel) 11(9):1354. https://doi.org/10.3390/cancers11091354CrossRefPubMed

Cao W, Chen HD, Yu YW, Li N, Chen WQ (2021) Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (engl) 134(7):783–791CrossRefPubMed

Caylioglu D, Meyer RJ, Hellmold D, Kubelt C, Synowitz M, Held-Feindt J (2021) Effects of the Anti-Tumorigenic Agent AT101 on human glioblastoma cells in the microenvironmental glioma stem cell niche. Int J Mol Sci 22(7):3606. https://doi.org/10.3390/ijms22073606CrossRefPubMedPubMedCentral

Chandel NS (2021) Nucleotide Metabolism. Cold Spring Harb Perspect Biol 13(7):a040592. https://doi.org/10.1101/cshperspect.a040592CrossRefPubMedPubMedCentral

Chang HW, Lee M, Lee YS, Kim SH, Lee JC, Park JJ et al (2021) p53-dependent glutamine usage determines susceptibility to oxidative stress in radioresistant head and neck cancer cells. Cell Signal 77:109820. https://doi.org/10.1016/j.cellsig.2020.109820CrossRefPubMed

Chen L, Zhao J, Tang Q, Li H, Zhang C, Yu R et al (2016) PFKFB3 control of cancer growth by responding to circadian clock outputs. Sci Rep 6:24324. https://doi.org/10.1038/srep24324CrossRefPubMedPubMedCentral

Chi F, Sharpley MS, Nagaraj R, Roy SS, Banerjee U (2020) Glycolysis-independent glucose metabolism distinguishes te from icm fate during mammalian embryogenesis. Dev Cell 53(1):9-26.e4. https://doi.org/10.1016/j.devcel.2020.02.015CrossRefPubMedPubMedCentral

Ciscato F, Ferrone L, Masgras I, Laquatra C, Rasola A (2021) Hexokinase 2 in Cancer: a prima donna playing multiple characters. Int J Mol Sci 22(9):4716. https://doi.org/10.3390/ijms22094716CrossRefPubMedPubMedCentral

Clem BF, Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA et al (2013) Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Mol Cancer Ther 12(8):1461–1470. https://doi.org/10.1158/1535-7163.MCT-13-0097CrossRefPubMedPubMedCentral

Cormerais Y, Massard PA, Vucetic M, Giuliano S, Tambutté E, Durivault J et al (2018) The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5). J Biol Chem 293(8):2877–2887. https://doi.org/10.1074/jbc.RA117.001342CrossRefPubMedPubMedCentral

Counillon L, Bouret Y, Marchiq I, Pouyssegur J (2016) Na(+)/H(+) antiporter (NHE1) and lactate/H(+) symporters (MCTs) in pH homeostasis and cancer metabolism. Biochim Biophys Acta 1863:2465–2480. https://doi.org/10.1016/j.bbamcr.2016.02.018CrossRefPubMed

Cui R, Bai H, Cao G, Zhang Z (2020) The Role of Lysophosphatidic Acid Receptors in Ovarian Cancer: A Minireview. Crit Rev Eukaryot Gene Expr 30(3):265–272. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2020031091CrossRefPubMed

Curtis NJ, Mooney L, Hopcroft L, Michopoulos F, Whalley N, Zhong H et al (2017) Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumour activity. Oncotarget 8:69219–69236. https://doi.org/10.18632/oncotarget.18215CrossRefPubMedPubMedCentral

De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW, Cantelmo AR et al (2013) Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 154(3):651–663. https://doi.org/10.1016/j.cell.2013.06.037CrossRefPubMed

De Oliveira T, Goldhardt T, Edelmann M, Rogge T, Rauch K, Kyuchukov ND et al (2021) Effects of the Novel PFKFB3 Inhibitor KAN0438757 on Colorectal Cancer Cells and Its Systemic Toxicity Evaluation In Vivo. Cancers (basel). 13(5):1011. https://doi.org/10.3390/cancers13051011CrossRefPubMedPubMedCentral

De Paz Linares GA, Opperman RM, Majumder M, Lala PK (2021) Prostaglandin E2 Receptor 4 (EP4) as a Therapeutic Target to Impede Breast Cancer-Associated Angiogenesis and Lymphangiogenesis. Cancers (basel) 13(5):942. https://doi.org/10.3390/cancers13050942CrossRefPubMed

de Carvalho CCCR, Caramujo MJ (2018) The Various Roles of Fatty Acids. Molecules 23(10):2583. https://doi.org/10.3390/molecules23102583CrossRefPubMedPubMedCentral

de la Cruz-López KG, Castro-Muñoz LJ, Reyes-Hernández DO, García-Carrancá A, Manzo-Merino J (2019) Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches. Front Oncol 9:1143. https://doi.org/10.3389/fonc.2019.01143CrossRefPubMedPubMedCentral

Deskeuvre M, Lan J, Dierge E, Messens J, Riant O, Corbet C et al (2022) Targeting cancer cells in acidosis with conjugates between the carnitine palmitoyltransferase 1 inhibitor etomoxir and pH (low) insertion peptides. Int J Pharm 624:122041. https://doi.org/10.1016/j.ijpharm.2022.122041CrossRefPubMed

Ding X, Gu Y, Jin M, Guo X, Xue S, Tan C et al (2020) The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase. Theranostics 10(13):6048–6060. https://doi.org/10.7150/thno.42096CrossRefPubMedPubMedCentral

Doherty JR, Yang C, Scott KEN, Cameron MD, Fallahi M, Li W et al (2014) Blocking lactate export by inhibiting the Myc target MCT1 disables glycolysis and glutathione synthesis. Cancer Res 74:908–920. https://doi.org/10.1158/0008-5472.CAN-13-2034CrossRefPubMed

Doménech E, Maestre C, Esteban-Martínez L, Partida D, Pascual R, Fernández-Miranda G et al (2015) AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest. Nat Cell Biol 17(10):1304–1316. https://doi.org/10.1038/ncb3231CrossRefPubMed

Draoui N, Schicke O, Seront E, Bouzin C, Sonveaux P, Riant O et al (2014) Antitumor activity of 7-aminocarboxycoumarin derivatives, a new class of potent inhibitors of lactate influx but not efflux. Mol Cancer Ther 13(6):1410–1418. https://doi.org/10.1158/1535-7163.MCT-13-0653CrossRefPubMed

Ducker GS, Chen L, Morscher RJ, Ghergurovich JM, Esposito M, Teng X et al (2016) Reversal of Cytosolic One-Carbon Flux Compensates for Loss of the Mitochondrial Folate Pathway. Cell Metab 23(6):1140–1153. https://doi.org/10.1016/j.cmet.2016.04.016CrossRefPubMedPubMedCentral

Duman C, Yaqubi K, Hoffmann A, Acikgöz AA, Korshunov A, Bendszus M et al (2019) Acyl-CoA-Binding Protein Drives Glioblastoma Tumorigenesis by Sustaining Fatty Acid Oxidation. Cell Metab 30(2):274-289.e5. https://doi.org/10.1016/j.cmet.2019.04.004CrossRefPubMed

Edwards DN, Ngwa VM, Raybuck AL, Wang S, Hwang Y, Kim LC et al (2021) Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest 131(4):e140100. https://doi.org/10.1172/JCI140100CrossRefPubMedPubMedCentral

El Sayed SM, Mohamed WG, Seddik MA, Ahmed AS, Mahmoud AG, Amer WH et al (2014) Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study. Chin J Cancer 33(7):356–364. https://doi.org/10.5732/cjc.013.10111CrossRefPubMedPubMedCentral

Enomoto K, Sato F, Tamagawa S, Gunduz M, Onoda N, Uchino S et al (2019) A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1. Sci Rep 9(1):14616. https://doi.org/10.1038/s41598-019-51144-6CrossRefPubMedPubMedCentral

Fan TWM, Bruntz RC, Yang Y, Song H, Chernyavskaya Y, Deng P et al (2019) De novo synthesis of serine and glycine fuels purine nucleotide biosynthesis in human lung cancer tissues. J Biol Chem 294(36):13464–13477. https://doi.org/10.1074/jbc.RA119.008743CrossRefPubMedPubMedCentral

Farabegoli F, Vettraino M, Manerba M, Fiume L, Roberti M, Di Stefano G (2012) Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways. Eur J Pharm Sci 47(4):729–738. https://doi.org/10.1016/j.ejps.2012.08.012CrossRefPubMed

Feng Y, Xiong Y, Qiao T, Li X, Jia L, Han Y (2018) Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy. Cancer Med 7(12):6124–6136. https://doi.org/10.1002/cam4.1820CrossRefPubMedPubMedCentral

Fhu CW, Ali A (2020) Fatty Acid Synthase: An Emerging Target in Cancer. Molecules 25(17):3935. https://doi.org/10.3390/molecules25173935CrossRefPubMedPubMedCentral

Ganapathy-Kanniappan S (2018) Molecular intricacies of aerobic glycolysis in cancer: current insights into the classic metabolic phenotype. Crit Rev Biochem Mol Biol 53(6):667–682. https://doi.org/10.1080/10409238.2018.1556578CrossRefPubMed

Gao CL, Hou GG, Liu J, Ru T, Xu YZ, Zhao SY et al (2020) Synthesis and Target Identification of Benzoxepane Derivatives as Potential Anti-Neuroinflammatory Agents for Ischemic Stroke. Angew Chem Int Ed Engl 259(6):2429–2439. https://doi.org/10.1002/anie.201912489CrossRef

Geeraerts SL, Heylen E, De Keersmaecker K, Kampen KR (2021) The ins and outs of serine and glycine metabolism in cancer. Nat Metab 3(2):131–141. https://doi.org/10.1038/s42255-020-00329-9CrossRefPubMed

Ghanem N, El-Baba C, Araji K, El-Khoury R, Usta J, Darwiche N (2021) The Pentose Phosphate Pathway in Cancer: Regulation and Therapeutic Opportunities. Chemotherapy 66(5–6):179–191. https://doi.org/10.1159/000519784CrossRefPubMed

Goncalves MD, Hopkins BD, Cantley LC (2018) Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer. N Engl J Med 379(21):2052–2062. https://doi.org/10.1056/NEJMra1704560CrossRefPubMed

Gozzelino L, De Santis MC, Gulluni F, Hirsch E, Martini M (2020) PI(3,4)P2 Signaling in Cancer and Metabolism. Front Oncol 10:360. https://doi.org/10.3389/fonc.2020.00360CrossRefPubMedPubMedCentral

Granchi C (2018) ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism. Eur J Med Chem 157:1276–1291. https://doi.org/10.1016/j.ejmech.2018.09.001CrossRefPubMed

Guo XP, Zhang XY, Zhang SD (1991) Clinical trial on the effects of shikonin mixture on later stage lung cancer. Zhong Xi Yi Jie He Za Zhi 11(10):598–599PubMed

Häfliger P, Charles RP (2019) The L-Type Amino Acid Transporter LAT1-An Emerging Target in Cancer. Int J Mol Sci 20(10):2428. https://doi.org/10.3390/ijms20102428CrossRefPubMedPubMedCentral

Hager S, Fittler FJ, Wagner E, Bros M (2020) Nucleic Acid-Based Approaches for Tumor Therapy. Cells 9(9):2061. https://doi.org/10.3390/cells9092061CrossRefPubMedPubMedCentral

Hamada S, Matsumoto R, Tanaka Y, Taguchi K, Yamamoto M, Masamune A (2021) Nrf2 Activation Sensitizes K-Ras Mutant Pancreatic Cancer Cells to Glutaminase Inhibition. Int J Mol Sci 22(4):1870. https://doi.org/10.3390/ijms22041870CrossRefPubMedPubMedCentral

Han X, Sheng X, Jones HM, Jackson AL, Kilgore J, Stine JE et al (2015) Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells. J Hematol Oncol 8:2. https://doi.org/10.1186/s13045-014-0097-xCrossRefPubMedPubMedCentral

Han S, Wei R, Zhang X, Jiang N, Fan M, Huang JH et al (2019) CPT1A/2-Mediated FAO Enhancement-A Metabolic Target in Radioresistant Breast Cancer. Front Oncol 9:1201. https://doi.org/10.3389/fonc.2019.01201CrossRefPubMedPubMedCentral

Hayes JD, Dinkova-Kostova AT, Tew KD (2020) Oxidative Stress in Cancer. Cancer Cell 38(2):167–197. https://doi.org/10.1016/j.ccell.2020.06.001 (Epub 2020 Jul 9)CrossRefPubMedPubMedCentral

He ST, Lee DY, Tung CY, Li CY, Wang HC (2019) Glutamine Metabolism in Both the Oxidative and Reductive Directions Is Triggered in Shrimp Immune Cells (Hemocytes) at the WSSV Genome Replication Stage to Benefit Virus Replication. Front Immunol 10:2102. https://doi.org/10.3389/fimmu.2019.02102CrossRefPubMedPubMedCentral

He F, Antonucci L, Karin M (2020) NRF2 as a regulator of cell metabolism and inflammation in cancer. Carcinogenesis 41(4):405–416. https://doi.org/10.1093/carcin/bgaa039CrossRefPubMedPubMedCentral

He Y, He Z, Zhang X, Liu S (2021) Platelet-activating factor acetyl hydrolase IB2 dysregulated cell proliferation in ovarian cancer. Cancer Cell Int 21(1):697. https://doi.org/10.1186/s12935-021-02406-9CrossRefPubMedPubMedCentral

Hochster H (2002) The role of pemetrexed in the treatment of colorectal cancer. Semin Oncol 29(6 Suppl 18):54–56. https://doi.org/10.1053/sonc.2002.37473CrossRefPubMed

Holman GD (2020) Structure, function and regulation of mammalian glucose transporters of the SLC2 family. Pflugers Arch 472(9):1155–1175. https://doi.org/10.1007/s00424-020-02411-3CrossRefPubMedPubMedCentral

Hong B, van den Heuvel AP, Prabhu VV, Zhang S, El-Deiry WS (2014) Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Curr Drug Targets 15(1):80–89. https://doi.org/10.2174/1389450114666140106101412CrossRefPubMed

Hresko RC, Hruz PW (2011) HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4. PLoS ONE 6(9):e25237. https://doi.org/10.1371/journal.pone.0025237CrossRefPubMedPubMedCentral

Hu X, Jin H, Zhu L (2021) Effect of glutamine metabolism on chemoresistance and its mechanism in tumors. Zhejiang Da Xue Xue Bao Yi Xue Ban 50(1):32–40. https://doi.org/10.3724/zdxbyxb-2021-0040CrossRefPubMedPubMedCentral

İlhan M (2022) Non-metabolic functions of pyruvate kinase M2: PKM2 in tumorigenesis and therapy resistance. Neoplasma 69(4):747–754. https://doi.org/10.4149/neo_2022_220119N77CrossRefPubMed

Ishimoto K, Minami A, Minami K, Ueda N, Tsujiuchi T (2021) Different effects of lysophosphatidic acid receptor-2 (LPA2) and LPA5 on the regulation of chemoresistance in colon cancer cells. J Recept Signal Transduct Res 41(1):93–98. https://doi.org/10.1080/10799893.2020.1794002CrossRefPubMed

Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X et al (2018) Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell 172(3):578-589.e17. https://doi.org/10.1016/j.cell.2018.01.006CrossRefPubMed

Jang M, Kim SS, Lee J (2013) Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med 45(10):e45. https://doi.org/10.1038/emm.2013.85CrossRefPubMedPubMedCentral

Jara-Gutiérrez Á, Baladrón V (2021) The Role of Prostaglandins in Different Types of Cancer. Cells 10(6):1487. https://doi.org/10.3390/cells10061487CrossRefPubMedPubMedCentral

Jelic MD, Mandic AD, Maricic SM, Srdjenovic BU (2021) Oxidative stress and its role in cancer. J Cancer Res Ther 17(1):22–28. https://doi.org/10.4103/jcrt.JCRT_862_16CrossRefPubMed

Jiang M, Liu S, Lin J, Hao W, Wei B, Gao Y et al (2021) A pan-cancer analysis of molecular characteristics and oncogenic role of hexokinase family genes in human tumors. Life Sci 264:118669. https://doi.org/10.1016/j.lfs.2020.118669CrossRefPubMed

Jin L, Chun J, Pan C, Alesi GN, Li D, Magliocca KR et al (2017) Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis. Oncogene 36(27):3797–3806. https://doi.org/10.1038/onc.2017.6CrossRefPubMedPubMedCentral

Jin Z, Chai YD, Hu S (2021) Fatty Acid Metabolism and Cancer. Adv Exp Med Biol 1280:231–241. https://doi.org/10.1007/978-3-030-51652-9_16CrossRefPubMed

Jones SF, Infante JR (2015) Molecular Pathways: Fatty Acid Synthase. Clin Cancer Res 21(24):5434–5438. https://doi.org/10.1158/1078-0432.CCR-15-0126CrossRefPubMed

Kanai Y (2022) Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. Pharmacol Ther 230:107964. https://doi.org/10.1016/j.pharmthera.2021.107964CrossRefPubMed

Kenmotsu H, Yamamoto N, Yamanaka T, Yoshiya K, Takahashi T, Ueno T et al (2020) Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 38(19):2187–2196CrossRefPubMed

Keung W, Ussher JR, Jaswal JS, Raubenheimer M, Lam VHM, Wagg CS et al (2013) Inhibition of Carnitine Palmitoyltransferase-1 Activity Alleviates Insulin Resistance in Diet-Induced Obese Mice. Diabetes 62:711–720. https://doi.org/10.2337/db12-0259CrossRefPubMedPubMedCentral

Kim J, Hu Z, Cai L, Li K, Choi E, Faubert B et al (2017) CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature 546(7656):168–172. https://doi.org/10.1038/nature22359CrossRefPubMedPubMedCentral

Ko YH, Verhoeven HA, Lee MJ, Corbin DJ, Vogl TJ, Pedersen PL (2012) A translational study “case report” on the small molecule “energy blocker” 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. J Bioenerg Biomembr 44(1):163–170. https://doi.org/10.1007/s10863-012-9417-4CrossRefPubMed

Koppula P, Zhang Y, Zhuang L, Gan B (2018) Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun (lond) 38(1):12. https://doi.org/10.1186/s40880-018-0288-xCrossRefPubMed

Koundouros N, Poulogiannis G (2020) Reprogramming of fatty acid metabolism in cancer. Br J Cancer 122(1):4–22. https://doi.org/10.1038/s41416-019-0650-zCrossRefPubMed

Lane AN, Fan TW (2015) Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res 43(4):2466–2485. https://doi.org/10.1093/nar/gkv047CrossRefPubMedPubMedCentral

Lee EA, Angka L, Rota SG, Hanlon T, Mitchell A, Hurren R et al (2015) Targeting Mitochondria with Avocatin B Induces Selective Leukemia Cell Death. Cancer Res 75(12):2478–2488. https://doi.org/10.1158/0008-5472.CAN-14-2676CrossRefPubMed

Lemberg KM, Vornov JJ, Rais R, Slusher BS (2018) We’re Not “DON” Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-Oxo-L-Norleucine. Mol Cancer 17:1824–1832. https://doi.org/10.1158/1535-7163.MCT-17-1148CrossRef

Li T, Le A (2018) Glutamine Metabolism in Cancer. Adv Exp Med Biol 1063:13–32. https://doi.org/10.1007/978-3-319-77736-8_2CrossRefPubMed

Li HM, Yang JG, Liu ZJ, Wang WM, Yu ZL, Ren JG et al (2017a) Blockage of glycolysis by targeting PFKFB3 suppresses tumor growth and metastasis in head and neck squamous cell carcinoma. J Exp Clin Cancer Res 36(1):7. https://doi.org/10.1186/s13046-016-0481-1CrossRefPubMedPubMedCentral

Li W, Zheng M, Wu S, Gao S, Yang M, Li Z et al (2017b) Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2. J Exp Clin Cancer Res 36(1):58. https://doi.org/10.1186/s13046-017-0530-4CrossRefPubMedPubMedCentral

Li EQ, Zhao W, Zhang C, Qin LZ, Liu SJ, Feng ZQ et al (2019) Synthesis and anti-cancer activity of ND-646 and its derivatives as acetyl-CoA carboxylase 1 inhibitors. Eur J Pharm Sci 137:105010. https://doi.org/10.1016/j.ejps.2019.105010CrossRefPubMed

Ling G, Lamprecht S, Shubinsky G, Osyntsov L, Yerushalmi B, Pinsk I et al (2018) Mycophenolate Mofetil Alone and in Combination with Tacrolimus Inhibits the Proliferation of HT-29 Human Colonic Adenocarcinoma Cell Line and Might Interfere with Colonic Tumorigenesis. Anticancer Res 38(6):3333–3339. https://doi.org/10.21873/anticanres.12599CrossRefPubMed

Ling R, Chen G, Tang X, Liu N, Zhou Y, Chen D (2022) Acetyl-CoA synthetase 2(ACSS2): a review with a focus on metabolism and tumor development. Discov Oncol 13(1):58. https://doi.org/10.1007/s12672-022-00521-1CrossRefPubMedPubMedCentral

Liu J, Zhang C, Lin M, Zhu W, Liang Y, Hong X et al (2014) Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma. Oncotarget 5(9):2635–2647. https://doi.org/10.18632/oncotarget.1862CrossRefPubMedPubMedCentral

Liu P, Liu J, Jiang W, Carew JS, Ogasawara MA, Pelicano H et al (2016) Elimination of Chronic Lymphocytic Leukemia Cells in Stromal Microenvironment by Targeting CPT with an Anti-Angina Drug Perhexiline. Oncogene 35:5663–5673. https://doi.org/10.1038/onc.2016.103CrossRefPubMedPubMedCentral

Long Y, Qiu J, Zhang B, He P, Shi X, He Q et al (2021) Pharmacological Vitamin C Treatment Impedes the Growth of Endogenous Glutamine-Dependent Cancers by Targeting Glutamine Synthetase. Front Pharmacol 12:671902. https://doi.org/10.3389/fphar.2021.671902CrossRefPubMedPubMedCentral

Lopes C, Pereira C, Medeiros R (2021) ASCT2 and LAT1 Contribution to the Hallmarks of Cancer: From a Molecular Perspective to Clinical Translation. Cancers (basel) 13(2):203. https://doi.org/10.3390/cancers13020203CrossRefPubMed

Lordan R, Tsoupras A, Zabetakis I (2019) The Potential Role of Dietary Platelet-Activating Factor Inhibitors in Cancer Prevention and Treatment. Adv Nutr 10(1):148–164. https://doi.org/10.1093/advances/nmy090CrossRefPubMedPubMedCentral

Lu X (2019) The Role of Large Neutral Amino Acid Transporter (LAT1) in Cancer. Curr Cancer Drug Targets 19(11):863–876. https://doi.org/10.2174/1568009619666190802135714CrossRefPubMed

Lu L, Chen Y, Zhu Y (2017) The molecular basis of targeting PFKFB3 as a therapeutic strategy against cancer. Oncotarget 8(37):62793–62802. https://doi.org/10.18632/oncotarget.19513CrossRefPubMedPubMedCentral

Ma Y, Temkin SM, Hawkridge AM, Guo C, Wang W, Wang XY et al (2018) Fatty acid oxidation: An emerging facet of metabolic transformation in cancer. Cancer Lett 435:92–100. https://doi.org/10.1016/j.canlet.2018.08.006CrossRefPubMedPubMedCentral

Ma Y, Zhu Q, Wang X, Liu M, Chen Q, Jiang L et al (2022) Synthetic lethal screening identifies DHODH as a target for MEN1-mutated tumor cells. Cell Res 32(6):596–599. https://doi.org/10.1038/s41422-022-00613-1CrossRefPubMedPubMedCentral

Maher JC, Krishan A, Lampidis TJ (2004) Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol 53(2):116–122. https://doi.org/10.1007/s00280-003-0724-7CrossRefPubMed

Manerba M, Vettraino M, Fiume L, Di Stefano G, Sartini A, Giacomini E et al (2012) Galloflavin (CAS 568–80-9): a novel inhibitor of lactate dehydrogenase. ChemMedChem 7(2):311–317. https://doi.org/10.1002/cmdc.201100471CrossRefPubMed

Manerba M, Di Ianni L, Govoni M, Roberti M, Recanatini M, Di Stefano G (2017) LDH inhibition impacts on heat shock response and induces senescence of hepatocellular carcinoma cells. Eur J Pharm Sci 105:91–98. https://doi.org/10.1016/j.ejps.2017.05.015CrossRefPubMed

Mao S, Ling Q, Pan J, Li F, Huang S, Ye W et al (2021) Inhibition of CPT1a as a prognostic marker can synergistically enhance the antileukemic activity of ABT199. J Transl Med 19(1):181. https://doi.org/10.1186/s12967-021-02848-9CrossRefPubMedPubMedCentral

Martelli MP, Martino G, Cardinali V, Falini B, Martinelli G, Cerchione C (2020) Enasidenib and ivosidenib in AML. Minerva Med 111(5):411–426. https://doi.org/10.23736/S0026-4806.20.07024-XCrossRefPubMed

Martinez RS, Salji MJ, Rushworth L, Ntala C, Rodriguez Blanco G, Hedley A et al (2021) SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer. Cancer Res 81(13):3664–3678. https://doi.org/10.1158/0008-5472.CAN-20-3694CrossRefPubMed

Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, Sotgia F, Lisanti MP (2017) Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol 14(1):11–31. https://doi.org/10.1038/nrclinonc.2016.60CrossRefPubMed

Mascagna D, Ghanem G, Morandini R, d’Ischia M, Misuraca G, Lejeune F et al (1992) Synthesis and cytotoxic properties of new N-substituted 4-aminophenol derivatives with a potential as antimelanoma agents. Melanoma Res 2(1):25–32. https://doi.org/10.1097/00008390-199205000-00004CrossRefPubMed

Matés JM, Di Paola FJ, Campos-Sandoval JA, Mazurek S, Márquez J (2020) Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer. Semin Cell Dev Biol 98:34–43. https://doi.org/10.1016/j.semcdb.2019.05.012CrossRefPubMed

Mathur D, Stratikopoulos E, Ozturk S, Steinbach N, Pegno S, Schoenfeld S et al (2017) PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition. Cancer Discov 7(4):380–390. https://doi.org/10.1158/2159-8290.CD-16-0612CrossRefPubMedPubMedCentral

McAnulty J, DiFeo A (2020) The Molecular “Myc-anisms” Behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics. Int J Mol Sci 21(24):9486. https://doi.org/10.3390/ijms21249486CrossRefPubMedPubMedCentral

McDonald PC, Chafe SC, Brown WS, Saberi S, Swayampakula M, Venkateswaran G et al (2019) Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. Gastroenterology 157(3):823–837. https://doi.org/10.1053/j.gastro.2019.05.004CrossRefPubMed

McDonald G, Chubukov V, Coco J, Truskowski K, Narayanaswamy R, Choe S et al (2020) Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase. Mol Cancer Ther 19(12):2502–2515. https://doi.org/10.1158/1535-7163.MCT-20-0550CrossRefPubMed

Mikalayeva V, Ceslevičienė I, Sarapinienė I, Žvikas V, Skeberdis VA, Jakštas V et al (2019) Fatty Acid Synthesis and Degradation Interplay to Regulate the Oxidative Stress in Cancer Cells. Int J Mol Sci 20(6):1348. https://doi.org/10.3390/ijms20061348CrossRefPubMedPubMedCentral

Mizuno R, Kawada K, Sakai Y (2019) Prostaglandin E2/EP Signaling in the Tumor Microenvironment of Colorectal Cancer. Int J Mol Sci 20(24):6254. https://doi.org/10.3390/ijms20246254CrossRefPubMedPubMedCentral

Moloney JN, Cotter TG (2018) ROS signalling in the biology of cancer. Semin Cell Dev Biol 80:50–64. https://doi.org/10.1016/j.semcdb.2017.05.023CrossRefPubMed

Mondal S, Roy D, Sarkar Bhattacharya S, Jin L, Jung D, Zhang S et al (2019) Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers. Int J Cancer 144(1):178–189. https://doi.org/10.1002/ijc.31868CrossRefPubMed

Mukha A, Kahya U, Linge A, Chen O, Löck S, Lukiyanchuk V et al (2021) GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. Theranostics 11(16):7844–7868. https://doi.org/10.7150/thno.58655CrossRefPubMedPubMedCentral

Muto Y, Furihata T, Kaneko M, Higuchi K, Okunushi K, Morio H, Reien Y, Uesato M, Matsubara H, Anzai N (2019) Different Response Profiles of Gastrointestinal Cancer Cells to an L-Type Amino Acid Transporter Inhibitor, JPH203. Anticancer Res 39(1):159–165. https://doi.org/10.21873/anticanres.13092 (PMID: 30591453)CrossRefPubMed

Nagana Gowda GA, Barding GA Jr, Dai J, Gu H, Margineantu DH, Hockenbery DM et al (2018) A Metabolomics Study of BPTES Altered Metabolism in Human Breast Cancer Cell Lines. Front Mol Biosci 5:49. https://doi.org/10.3389/fmolb.2018.00049CrossRefPubMedPubMedCentral

Nam JS, Sharma AR, Nguyen LT, Jagga S, Lee YH, Sharma G et al (2018) Lysophosphatidic acid enhances breast cancer cells-mediated osteoclastogenesis. Korean J Physiol Pharmacol 22(5):503–511. https://doi.org/10.4196/kjpp.2018.22.5.503CrossRefPubMedPubMedCentral

Ning X, Qi H, Li R, Li Y, Jin Y, McNutt MA et al (2017) Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase. Eur J Med Chem 138:343–352. https://doi.org/10.1016/j.ejmech.2017.06.064CrossRefPubMed

Nishikubo K, Ohgaki R, Okanishi H, Okuda S, Xu M, Endou H et al (2022) Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells. J Cell Mol Med 26(20):5246–5256. https://doi.org/10.1111/jcmm.17553CrossRefPubMedPubMedCentral

Oda K, Hosoda N, Endo H, Saito K, Tsujihara K, Yamamura M et al (2010) L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci 101(1):173–179. https://doi.org/10.1111/j.1349-7006.2009.01386.xCrossRefPubMed

Okano N, Naruge D, Kawai K, Kobayashi T, Nagashima F, Endou H, Furuse J (2020) First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors. Invest New Drugs 38(5):1495–1506. https://doi.org/10.1007/s10637-020-00924-3CrossRefPubMed

Okesli A, Khosla C, Bassik MC (2017) Human pyrimidine nucleotide biosynthesis as a target for antiviral chemotherapy. Curr Opin Biotechnol 48:127–134. https://doi.org/10.1016/j.copbio.2017.03.010CrossRefPubMedPubMedCentral

Pacilli A, Calienni M, Margarucci S, D’Apolito M, Petillo O, Rocchi L et al (2013) Carnitine-acyltransferase system inhibition, cancer cell death, and prevention of myc-induced lymphomagenesis. J Natl Cancer Inst 105(7):489–498. https://doi.org/10.1093/jnci/djt030CrossRefPubMed

Pajak B, Siwiak E, Sołtyka M, Priebe A, Zieliński R, Fokt I et al (2019) 2-Deoxy-d-Glucose and Its Analogs From Diagnostic to Therapeutic Agents. Int J Mol Sci 21(1):234CrossRefPubMedPubMedCentral

Park JH, Kundu A, Lee SH, Jiang C, Lee SH, Kim YS et al (2021) Specific Pyruvate Kinase M2 Inhibitor, Compound 3K, Induces Autophagic Cell Death through Disruption of the Glycolysis Pathway in Ovarian Cancer Cells. Int J Biol Sci 17(8):1895–1908. https://doi.org/10.7150/ijbs.59855CrossRefPubMedPubMedCentral

Park JH, Lee JS, Oh Y, Lee JS, Park HE, Lee H et al (2022) PKM2 Is Overexpressed in Glioma Tissues, and Its Inhibition Highly Increases Late Apoptosis in U87MG Cells With Low-density Specificity. In Vivo 36(2):694–703. https://doi.org/10.21873/invivo.12755CrossRefPubMedPubMedCentral

Pavlova NN, Zhu J, Thompson CB (2022) The hallmarks of cancer metabolism: Still emerging. Cell Metab 34(3):355–377. https://doi.org/10.1016/j.cmet.2022.01.007CrossRefPubMedPubMedCentral

Pezzuto A, Carico E (2018) Role of HIF-1 in Cancer Progression: Novel Insights. A Review Curr Mol Med 18(6):343–351. https://doi.org/10.2174/1566524018666181109121849CrossRefPubMed

Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F (2012) Role of monocarboxylate transporters in human cancers: State of the art. J Bioenerg Biomembr 44:127–139. https://doi.org/10.1007/s10863-012-9428-1CrossRefPubMed

Prochownik EV, Wang H (2021) The Metabolic Fates of Pyruvate in Normal and Neoplastic Cells. Cells 10(4):762. https://doi.org/10.3390/cells10040762CrossRefPubMedPubMedCentral

Rais R, Jančařík A, Tenora L, Nedelcovych M, Alt J, Englert J et al (2016) Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma. J Med Chem 59(18):8621–8633. https://doi.org/10.1021/acs.jmedchem.6b01069CrossRefPubMed

Rais R, Lemberg KM, Tenora L, Arwood ML, Pal A, Alt J et al (2022) Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug. Sci Adv 8(46):5925. https://doi.org/10.1126/sciadv.abq5925CrossRef

Rani R, Kumar V (2016) Recent Update on Human Lactate Dehydrogenase Enzyme 5 (hLDH5) Inhibitors: A Promising Approach for Cancer Chemotherapy. J Med Chem 59(2):487–496. https://doi.org/10.1021/acs.jmedchem.5b00168CrossRefPubMed

Reis LMD, Adamoski D, Ornitz Oliveira Souza R, Rodrigues Ascenção CF, Sousa de Oliveira KR, Corrêa-da-Silva F et al (2019) Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells. J Biol Chem 294(24):9342–9357. https://doi.org/10.1074/jbc.RA119.008180CrossRefPubMedPubMedCentral

Renner O, Mayer M, Leischner C, Burkard M, Berger A, Lauer UM et al (2022) Systematic Review of Gossypol/AT-101 in Cancer Clinical Trials. Pharmaceuticals (basel) 15(2):144. https://doi.org/10.3390/ph15020144CrossRefPubMed

Ribera Santasusana JM (2020) Acute lymphoblastic leukemia: From aminopterin to CAR T cells. Med Clin (barc) 154(7):269–274. https://doi.org/10.1016/j.medcli.2019.09.011CrossRefPubMed

Roca Suarez AA, Testoni B, Baumert TF, Lupberger J (2021) Nucleic Acid-Induced Signaling in Chronic Viral Liver Disease. Front Immunol 11:624034. https://doi.org/10.3389/fimmu.2020.624034CrossRefPubMedPubMedCentral

Rodríguez-Nogales C, Sebastián V, Irusta S, Desmaële D, Couvreur P, Blanco-Prieto MJ (2019) A unique multidrug nanomedicine made of squalenoyl-gemcitabine and alkyl-lysophospholipid edelfosine. Eur J Pharm Biopharm 144:165–173. https://doi.org/10.1016/j.ejpb.2019.09.017CrossRefPubMed

Romer E, Thyagarajan A, Krishnamurthy S, Rapp CM, Liu L, Fahy K et al (2018) Systemic Platelet-Activating Factor-Receptor Agonism Enhances Non-Melanoma Skin Cancer Growth. Int J Mol Sci 19(10):3109. https://doi.org/10.3390/ijms19103109CrossRefPubMedPubMedCentral

Rosilio C, Nebout M, Imbert V, Griessinger E, Neffati Z, Benadiba J et al (2015) L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia. Leukemia 29(6):1253–1266. https://doi.org/10.1038/leu.2014.338 (Epub 2014 Dec 8)CrossRefPubMed

Sajadimajd S, Khazaei M (2018) Oxidative Stress and Cancer: The Role of Nrf2. Curr Cancer Drug Targets 18(6):538–557. https://doi.org/10.2174/1568009617666171002144228CrossRefPubMed

Sarkar Bhattacharya S, Thirusangu P, Jin L, Roy D, Jung D, Xiao Y et al (2019) PFKFB3 inhibition reprograms malignant pleural mesothelioma to nutrient stress-induced macropinocytosis and ER stress as independent binary adaptive responses. Cell Death Dis 10(10):725. https://doi.org/10.1038/s41419-019-1916-3CrossRefPubMedPubMedCentral

Sarniak A, Lipińska J, Tytman K, Lipińska S (2016) Endogenous mechanisms of reactive oxygen species (ROS) generation. Postepy Hig Med Dosw (online) 70:1150–1165. https://doi.org/10.5604/17322693.1224259CrossRefPubMed

Schlaepfer IR, Joshi M (2020) CPT1A-mediated Fat Oxidation, Mechanisms, and Therapeutic Potential. Endocrinology 161(2):046. https://doi.org/10.1210/endocr/bqz046CrossRef

Schoors S, De Bock K, Cantelmo AR, Georgiadou M, Ghesquière B, Cauwenberghs S et al (2014) Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab 19(1):37–48. https://doi.org/10.1016/j.cmet.2013.11.008CrossRefPubMed

Schulte ML, Fu A, Zhao P, Li J, Geng L, Smith ST et al (2018) Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. Nat Med 24(2):194–202. https://doi.org/10.1038/nm.4464CrossRefPubMedPubMedCentral

Serganova I, Cohen IJ, Vemuri K, Shindo M, Maeda M, Mane M et al (2018) LDH-A regulates the tumor microenvironment via HIF-signaling and modulates the immune response. PLoS ONE 13(9):e0203965. https://doi.org/10.1371/journal.pone.0203965CrossRefPubMedPubMedCentral

Sharma NS, Gupta VK, Garrido VT, Hadad R, Durden BC, Kesh K et al (2020) Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Invest 130(1):451–465. https://doi.org/10.1172/JCI127515CrossRefPubMed

Shi L, Pan H, Liu Z, Xie J, Han W (2017) Roles of PFKFB3 in cancer. Signal Transduct Target Ther 2:17044. https://doi.org/10.1038/sigtrans.2017.44CrossRefPubMedPubMedCentral

Shima T, Taniguchi K, Tokumaru Y, Inomata Y, Arima J, Lee SW et al (2022) Glucose transporter-1 inhibition overcomes imatinib resistance in gastrointestinal stromal tumor cells. Oncol Rep 47(1):7. https://doi.org/10.3892/or.2021.8218CrossRefPubMed

Siebeneicher H, Cleve A, Rehwinkel H, Neuhaus R, Heisler I, Müller T et al (2016) Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876. ChemMedChem 11(20):2261–2271. https://doi.org/10.1002/cmdc.201600276CrossRefPubMedPubMedCentral

Siebert A, Deptuła M, Cichorek M, Ronowska A, Cholewiński G, Rachon J (2021) Anticancer Properties of Amino Acid and Peptide Derivatives of Mycophenolic Acid. Anticancer Agents Med Chem 21(4):462–467. https://doi.org/10.2174/1871520620666200516151456CrossRefPubMed

Siegel RL, Miller KD, Jemal A (2020) Cancer statistics. CA. Cancer J Clin 70:7–30. https://doi.org/10.3322/caac.21590CrossRef

Sies H, Jones DP (2020) Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol 21(7):363–383. https://doi.org/10.1038/s41580-020-0230-3 (Epub 2020 Mar 30)CrossRefPubMed

Singleton DC, Dechaume AL, Murray PM, Katt WP, Baguley BC, Leung EY (2020) Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer. BMC Cancer 20(1):470. https://doi.org/10.1186/s12885-020-06885-3CrossRefPubMedPubMedCentral

Sipos A, Ujlaki G, Mikó E, Maka E, Szabó J, Uray K et al (2021) The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling. Mol Med 27(1):33. https://doi.org/10.1186/s10020-021-00295-2CrossRefPubMedPubMedCentral

Snaebjornsson MT, Janaki-Raman S, Schulze A (2020) Greasing the Wheels of the Cancer Machine: The Role of Lipid Metabolism in Cancer. Cell Metab 31(1):62–76. https://doi.org/10.1016/j.cmet.2019.11.010CrossRefPubMed

Song S, Chen Q, Li Y, Lei G, Scott A, Huo L et al (2021) Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. Gut 70(12):2238–2248. https://doi.org/10.1136/gutjnl-2020-321175CrossRefPubMed

Soth MJ, Le K, Di Francesco ME, Hamilton MM, Liu G, Burke JP et al (2020) Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. J Med Chem 63(21):12957–12977. https://doi.org/10.1021/acs.jmedchem.0c01398CrossRefPubMedPubMedCentral

Still ER, Yuneva MO (2017) Hopefully devoted to Q: targeting glutamine addiction in cancer. Br Cancer. 116(11):1375–1381. https://doi.org/10.1038/bjc.2017.113CrossRef

Sullivan LB, Gui DY, Hosios AM, Bush LN, Freinkman E, Vander Heiden MG (2015) Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells. Cell 162(3):552–563. https://doi.org/10.1016/j.cell.2015.07.017CrossRefPubMedPubMedCentral

Sun S, Li H, Chen J, Qian Q (2017) Lactic Acid: No Longer an Inert and End-Product of Glycolysis. Physiology (bethesda) 32(6):453–463. https://doi.org/10.1152/physiol.00016.2017CrossRefPubMed

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed

Suzuki K, Miura Y, Mochida Y, Miyazaki T, Toh K, Anraku Y et al (2019) Glucose transporter 1-mediated vascular translocation of nanomedicines enhances accumulation and efficacy in solid tumors. J Control Release 301:28–41. https://doi.org/10.1016/j.jconrel.2019.02.021CrossRefPubMed

Svensson RU, Shaw RJ (2016) Lipid Synthesis Is a Metabolic Liability of Non-Small Cell Lung Cancer. Cold Spring Harb Symp Quant Biol 81:93–103. https://doi.org/10.1101/sqb.2016.81.030874 (Epub 2017 Jan 6)CrossRefPubMed

Syed-Abdul MM, Parks EJ, Gaballah AH, Bingham K, Hammoud GM, Kemble G et al (2020) Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities. Hepatology 72(1):103–118. https://doi.org/10.1002/hep.31000CrossRefPubMed

Tambay V, Raymond VA, Bilodeau M (2021) MYC Rules: Leading Glutamine Metabolism toward a Distinct Cancer Cell Phenotype. Cancers (basel) 13(17):4484. https://doi.org/10.3390/cancers13174484CrossRefPubMed

Tang Z, Xu Z, Zhu X, Zhang J (2021) New insights into molecules and pathways of cancer metabolism and therapeutic implications. Cancer Commun 41(1):16–36CrossRef

Tang M, Dong X, Xiao L, Tan Z, Luo X, Yang L et al (2022) CPT1A-mediated fatty acid oxidation promotes cell proliferation via nucleoside metabolism in nasopharyngeal carcinoma. Cell Death Dis 13(4):331. https://doi.org/10.1038/s41419-022-04730-yCrossRefPubMedPubMedCentral

Tannir NM et al (2021) CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies. J Clin Oncol 39:4501–4501CrossRef

Tao L, Wei L, Liu Y, Ding Y, Liu X, Zhang X et al (2017) Gen-27, a newly synthesized flavonoid, inhibits glycolysis and induces cell apoptosis via suppression of hexokinase II in human breast cancer cells. Biochem Pharmacol 125:12–25. https://doi.org/10.1016/j.bcp.2016.11.001CrossRefPubMed

Tao T, Su Q, Xu S, Deng J, Zhou S, Zhuang Y et al (2019) Down-regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP-1c axis. J Cell Physiol 234(3):3088–3104. https://doi.org/10.1002/jcp.27129CrossRefPubMed

Teixeira E, Silva C, Martel F (2021) The role of the glutamine transporter ASCT2 in antineoplastic therapy. Cancer Chemother Pharmacol 87(4):447–464. https://doi.org/10.1007/s00280-020-04218-6CrossRefPubMed

Valvona CJ, Fillmore HL, Nunn PB, Pilkington GJ (2016) The regulation and function of lactate dehydrogenase a: therapeutic potential in brain tumor. Brain Pathol 26(1):3–17. https://doi.org/10.1111/bpa.12299CrossRefPubMed

Vaupel P, Multhoff G (2021) Revisiting the Warburg effect: historical dogma versus current understanding. J Physiol 599(6):1745–1757. https://doi.org/10.1113/JP278810CrossRefPubMed

Ventura R, Mordec K, Waszczuk J, Wang Z, Lai J, Fridlib M et al (2015) Inhibition of de novo Palmitate synthesis by fatty acid synthase induces apoptosis in tumor cells by remodeling cell membranes, inhibiting signaling pathways, and reprogramming gene expression. EBioMedicine 2(8):808–824. https://doi.org/10.1016/j.ebiom.2015.06.020CrossRefPubMedPubMedCentral

Wahlström T, Henriksson MA (2015) Impact of MYC in regulation of tumor cell metabolism. Biochim Biophys Acta 1849(5):563–569. https://doi.org/10.1016/j.bbagrm.2014.07.004CrossRefPubMed

Wang Z, Wang N, Chen J, Shen J (2012) Emerging glycolysis targeting and drug discovery from chinese medicine in cancer therapy. Evid Based CompL Alternat Med 2012:873175. https://doi.org/10.1155/2012/873175CrossRef

Wang X, Jung YS, Jun S, Lee S, Wang W, Schneider A et al (2016) PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness. Nat Commun 7:10633. https://doi.org/10.1038/ncomms10633CrossRefPubMedPubMedCentral

Wang Y, Hao F, Nan Y, Qu L, Na W, Jia C et al (2018a) PKM2 Inhibitor shikonin overcomes the cisplatin resistance in bladder cancer by inducing necroptosis. Int J Biol Sci 14(13):1883–1891. https://doi.org/10.7150/ijbs.27854CrossRefPubMedPubMedCentral

Wang Y, Branicky R, Noë A, Hekimi S (2018b) Superoxide dismutases: dual roles in controlling ros damage and regulating ros signaling. J Cell Biol 217(6):1915–1928. https://doi.org/10.1083/jcb.201708007CrossRefPubMedPubMedCentral

Wang K, Jiang J, Lei Y, Zhou S, Wei Y, Huang C (2019) Targeting metabolic-redox circuits for cancer therapy. Trends Biochem Sci 44(5):401–414. https://doi.org/10.1016/j.tibs.2019.01.001CrossRefPubMed

Wang Y, Qu C, Liu T, Wang C (2020a) PFKFB3 inhibitors as potential anticancer agents: Mechanisms of action, current developments, and structure-activity relationships. Eur J Med Chem 203:112612. https://doi.org/10.1016/j.ejmech.2020.112612CrossRefPubMed

Wang JX, Choi SYC, Niu X, Kang N, Xue H, Killam J et al (2020b) Lactic acid and an acidic tumor microenvironment suppress anticancer immunity. Int J Mol Sci 21(21):8363. https://doi.org/10.3390/ijms21218363CrossRefPubMedPubMedCentral

Wang J, Liu R, Zhao Y, Ma Z, Sang Z, Wen Z et al (2021a) Novel microcrystal formulations of sorafenib facilitate a long-acting antitumor effect and relieve treatment side effects as observed with fundus microcirculation imaging. Front Oncol 11:743055. https://doi.org/10.3389/fonc.2021.743055CrossRefPubMedPubMedCentral

Wang Y, Qin L, Chen W, Chen Q, Sun J, Wang G (2021b) Novel strategies to improve tumour therapy by targeting the proteins MCT1, MCT4 and LAT1. Eur J Med Chem 226:113806. https://doi.org/10.1016/j.ejmech.2021.113806CrossRefPubMed

Wang JJ, Siu MK, Jiang YX, Leung TH, Chan DW, Wang HG et al (2021c) A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer. Biomolecules 11(12):1749. https://doi.org/10.3390/biom11121749CrossRefPubMedPubMedCentral

Wang W, Pan H, Ren F, Chen H, Ren P (2022a) Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells. Biosci Rep 42(3):B20212171. https://doi.org/10.1042/BSR20212171CrossRef

Wang Q, Morris RJ, Bode AM, Zhang T (2022b) Prostaglandin pathways: opportunities for cancer prevention and therapy. Cancer Res 82(6):949–965. https://doi.org/10.1158/0008-5472.CAN-21-2297CrossRefPubMedPubMedCentral

Wendt EHU, Schoenrogge M, Vollmar B, Zechner D (2020) Galloflavin plus metformin treatment impairs pancreatic cancer cells. Anticancer Res 40(1):153–160. https://doi.org/10.21873/anticanres.13936CrossRefPubMed

Yamashita AS, da Costa RM, Stumpo V, Rais R, Slusher BS, Riggins GJ (2020) The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling. Neurooncol Adv. 3(1):149. https://doi.org/10.1093/noajnl/vdaa149CrossRef

Yang H, Zhang MZ, Sun HW, Chai YT, Li X, Jiang Q et al (2021a) A novel microcrystalline bay-876 formulation achieves long-acting antitumor activity against aerobic glycolysis and proliferation of hepatocellular carcinoma. Front Oncol 11:783194. https://doi.org/10.3389/fonc.2021.783194CrossRefPubMedPubMedCentral

Yang Z, Zhang L, Zhu H, Zhou K, Wang H, Wang Y et al (2021b) Nanoparticle formulation of mycophenolate mofetil achieves enhanced efficacy against hepatocellular carcinoma by targeting tumour-associated fibroblast. J Cell Mol Med 25(7):3511–3523. https://doi.org/10.1111/jcmm.16434CrossRefPubMedPubMedCentral

Ye J, Huang Q, Xu J, Huang J, Wang J, Zhong W et al (2018) Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth. J Cancer Res Clin Oncol 144(5):821–833. https://doi.org/10.1007/s00432-018-2605-9CrossRefPubMedPubMedCentral

Yokoyama Y, Estok TM, Wild R (2022) Sirpiglenastat (DRP-104) induces antitumor efficacy through direct, broad antagonism of glutamine metabolism and stimulation of the innate and adaptive immune systems. Mol Cancer Ther 21(10):1561–1572. https://doi.org/10.1158/1535-7163.MCT-22-0282CrossRefPubMed

Yoo HC, Yu YC, Sung Y, Han JM (2020) Glutamine reliance in cell metabolism. Exp Mol Med 52(9):1496–1516. https://doi.org/10.1038/s12276-020-00504-8CrossRefPubMedPubMedCentral

Yothaisong S, Dokduang H, Anzai N, Hayashi K, Namwat N, Yongvanit P, Sangkhamanon S, Jutabha P, Endou H, Loilome W (2017) Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment. Tumour Biol 39(3):1010428317694545. https://doi.org/10.1177/1010428317694545CrossRefPubMed

Yu W, Huang J, Dong Q, Li W, Jiang L, Zhang Q et al (2022) Ag120-Mediated Inhibition of ASCT2-dependent glutamine transport has an anti-tumor effect on colorectal cancer cells. Front Pharmacol 13:871392. https://doi.org/10.3389/fphar.2022.871392CrossRefPubMedPubMedCentral

Yuan L, Sheng X, Clark LH, Zhang L, Guo H, Jones HM et al (2016) Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer. Am J Transl Res 8(10):4265–4277PubMedPubMedCentral

Yun J, Mullarky E, Lu C, Bosch KN, Kavalier A, Rivera K et al (2015) Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350(6266):1391–1396. https://doi.org/10.1126/science.aaa5004CrossRefPubMedPubMedCentral

Zahra K, Dey T, Ashish MSP, Pandey U (2020) Pyruvate Kinase M2 and Cancer: The Role of PKM2 in promoting tumorigenesis. Front Oncol 10:159. https://doi.org/10.3389/fonc.2020.00159CrossRefPubMedPubMedCentral

Zauri M, Berridge G, Thézénas ML, Pugh KM, Goldin R, Kessler BM et al (2015) CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer. Nature 524(7563):114–118. https://doi.org/10.1038/nature14948CrossRefPubMedPubMedCentral

Zaytseva YY, Rychahou PG, Le AT, Scott TL, Flight RM, Kim JT et al (2018) Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer. Oncotarget 9(37):24787–24800. https://doi.org/10.18632/oncotarget.25361CrossRefPubMedPubMedCentral

Ždralević M, Vučetić M, Daher B, Marchiq I, Parks SK, Pouysségur J (2018) Disrupting the “Warburg effect” re-routes cancer cells to OXPHOS offering a vulnerability point via ’ferroptosis’-induced cell death. Adv Biol Regul 68:55–63. https://doi.org/10.1016/j.jbior.2017.12.002CrossRefPubMed

Zeng Y (2018) Advances in mechanism and treatment strategy of cancer. Cell Mol Biol 64(6):1–3CrossRefPubMed

Zhang XD, Deslandes E, Villedieu M, Poulain L, Duval M, Gauduchon P et al (2006) Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro. Anticancer Res 26(5):3561–3566PubMed

Zhang D, Li J, Wang F, Hu J, Wang S, Sun Y (2014) 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. Cancer Lett 355(2):176–183. https://doi.org/10.1016/j.canlet.2014.09.003CrossRefPubMed

Zhang Z, Liu R, Shuai Y, Huang Y, Jin R, Wang X et al (2020) ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma. Br J Cancer 122(1):82–93. https://doi.org/10.1038/s41416-019-0637-9CrossRefPubMed

Zhao S, Jang C, Liu J, Uehara K, Gilbert M, Izzo L et al (2020) Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature 579(7800):586–591. https://doi.org/10.1038/s41586-020-2101-7CrossRefPubMedPubMedCentral

Zhelev Z, Aoki I, Lazarova D, Vlaykova T, Higashi T, Bakalova R (2022) A “Weird” mitochondrial fatty acid oxidation as a metabolic “secret” of cancer. Oxid Med Cell Longev. https://doi.org/10.1155/2022/2339584CrossRefPubMedPubMedCentral

Zheng M, Wu C, Yang K, Yang Y, Liu Y, Gao S et al (2021) Novel selective hexokinase 2 inhibitor Benitrobenrazide blocks cancer cells growth by targeting glycolysis. Pharmacol Res 164:105367. https://doi.org/10.1016/j.phrs.2020.105367CrossRefPubMed

Zhou Y, Huang Z, Su J, Li J, Zhao S, Wu L et al (2020) Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment. Int J Cancer 147(1):139–151. https://doi.org/10.1002/ijc.32756CrossRefPubMed

Zhou Y, Tao L, Zhou X, Zuo Z, Gong J, Liu X et al (2021) DHODH and cancer: promising prospects to be explored. Cancer Metab 9(1):22. https://doi.org/10.1186/s40170-021-00250-zCrossRefPubMedPubMedCentral

Zhu W, Ye L, Zhang J, Yu P, Wang H, Ye Z et al (2016) PFK15, a small molecule inhibitor of pfkfb3, induces cell cycle arrest, apoptosis and inhibits invasion in gastric cancer. PLoS ONE 2611(9):e0163768CrossRef

Zhu S, Guo Y, Zhang X, Liu H, Yin M, Chen X et al (2021) Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics. Cancer Lett 503:240–248. https://doi.org/10.1016/j.canlet.2020.11.018CrossRefPubMed

Zhu L, Li K, Liu M, Liu K, Ma S, Cai W (2022) Anti-cancer research on arnebiae radix-derived naphthoquinone in recent five years. Recent Pat Anticancer Drug Discov 17(3):218–230. https://doi.org/10.2174/1574892816666211209164745CrossRefPubMed

Zou J, Du K, Li S, Lu L, Mei J, Lin W et al (2021) Glutamine metabolism regulators associated with cancer development and the tumor microenvironment: a pan-cancer multi-omics analysis. Genes (basel). 12(9):1305. https://doi.org/10.3390/genes12091305CrossRefPubMedPubMedCentral

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Small molecule inhibitors for cancer metabolism: promising prospects to be explored

Abstract

Background

Purpose

Conclusion

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Purpose

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2023

Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach

Automatic breast cancer diagnosis based on hybrid dimensionality reduction technique and ensemble classification

The relationship of airflow limitation with lung squamous cell carcinoma: evidence from mendelian randomization analysis

Differential diagnosis of lymphoma with 18F-FDG PET/CT in patients with fever of unknown origin accompanied by lymphadenopathy

Standard deviation of CT radiomic features among malignancies in each individual: prognostic ability in lung cancer patients

Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials